“…However, controlled studies were carried out with highly selected RBD patient samples for example, patients with repeated suicide attempts or comorbid borderline personality disorder or somatic diseases (Kocmur, Dernovsek & Tavcar, 1998;Montgomery et al, 1994;Verkes et al, 1998;Wermuth et al, 1998), and this might have led to a bias directed towards therapy resistance. Our own positive experience concerning treatment with mirtazapine (Stamenkovic, Pezawas, De Zwaan, Aschauer, & Kasper, 1998), reboxetine (Pezawas et al, 2002a), and fluoxetine, as well as other positive results from case reports with lithium (Corominas, Bonet & Nieto, 1998), carbamazepine (Gertz, 1992), lamotrigine (Malt & Fladvad, 2001) and tranylcypromine (Joffe, 1996) put the negative findings from other studies due to the above mentioned reasons in question (Pezawas et al, 2001).…”